Search Within

Sara Kravetz

Formats
  1. Journal Article (7)
  2. Meeting Abstract (4)
Groups
  1. Department of Medicine (11)
  2. GDMT, Medicine (11)
  3. Gynecologic Medicine Service (11)
  4. Gynecology Disease Management Team (11)
  5. Solid Tumor Oncology Division (11)
  6. Biostatistics Service (7)

More Groups

People
  1. Carol Aghajanian (10)
  2. Paul Sabbatini (9)
  3. Alexia Iasonos (7)
  4. William Tew (7)
  5. Martee Hensley (6)
  6. Roisin O'Cearbhaill (6)

More People

Years
  1. 2023 (2)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (1)
  5. 2016 (1)
  6. 2013 (2)

More Years

Publications
  1. Journal of Clinical Oncology (3)
  2. Cancers (2)
  3. Cancer (1)
  4. Cancer Immunology, Immunotherapy (1)
  5. Clinical Cancer Research (1)
  6. Gynecologic Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (3)
  2. MDPI (2)
  3. American Association for Cancer Research (1)
  4. Biomed Central Ltd (1)
  5. Elsevier Inc. (1)
  6. Lippincott Williams & Wilkins (1)

More Publishers

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of a multivalent WT1 peptide vaccine (galinpepimut-S) in combination with nivolumab in patients with WT1-expressing ovarian cancer in second or third remission
    Journal Article

    Manning-Geist, B. L.; Gnjatic, S.; Aghajanian, C.; Konner, J.; Kim, S. H.; Sarasohn, D.; Soldan, K.; Tew, W. P.; Sarlis, N. J.; Zamarin, D.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination
    Journal Article

    Kahn, R. M.; Ragupathi, G.; Zhou, Q. C.; Iasonos, A.; Kravetz, S.; Hensley, M. L.; Konner, J. A.; Makker, V.; Tew, W. P.; Aghajanian, C.; more...
    Cancer Immunology, Immunotherapy (2023)

    Fulltext@MSK | Save
  • Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer
    Journal Article

    Kyi, C.; Doubrovina, E.; Zhou, Q.; Kravetz, S.; Iasonos, A.; Aghajanian, C.; Sabbatini, P.; Spriggs, D.; O'Reilly, R. J.; O'Cearbhaill, R. E.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
    Journal Article

    Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Boucicaut, N. N.; Henson, M.; Iasonos, A.; Zhou, Q.; Sarasohn, D. M.; Gallagher, J.; Kravetz, S.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • A phase 2 study of TPIV200/ huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer
    Meeting Abstract

    Zamarin, D.; Yeku, O.; O'Cearbhaill, R. E.; Cadoo, K. A.; Gallagher, J.; Kravetz, S.; McDonnell, A.; Troso-Sandoval, T.; Sabbatini, P.; Lichtman, S.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • A phase I study of unimolecular pentavalent (Globo-H-GM2-sTn-TF-Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission
    Journal Article

    O’Cearbhaill, R. E.; Ragupathi, G.; Zhu, J.; Wan, Q.; Mironov, S.; Yang, G.; Spassova, M. K.; Iasonos, A.; Kravetz, S.; Ouerfelli, O.; more...
    Cancers (2016)

    Fulltext@MSK | Save
  • A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma (UCS) with rhabdomyosarcoma (RMS) differentiation
    Meeting Abstract

    Makker, V.; Kravetz, S. J.; Gallagher, J.; Orodel, O.; Iasonos, A.; DeLair, D.; Zhou, Q.; Aghajanian, C.; Hensley, M. L.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Treatment outcomes in completely resected stage i to stage iv uterine carcinosarcoma with rhabdomyosarcoma differentiation
    Journal Article

    Makker, V.; Kravetz, S. J.; Gallagher, J.; Orodel, O. P.; Zhou, Q.; Iasonos, A.; DeLair, D.; Aghajanian, C.; Hensley, M. L.
    International Journal of Gynecological Cancer (2013)

    Fulltext@MSK | Save
  • Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study
    Journal Article

    Hensley, M. L.; Kravetz, S.; Jia, X.; Iasonos, A.; Tew, W.; Pereira, L.; Sabbatini, P.; Whalen, C.; Aghajanian, C. A.; Zarwan, C.; more...
    Cancer (2012)

    Fulltext@MSK | Save
  • Eribulin mesylate (halichondrin B analog E7389) in platinum-sensitive ovarian cancer: A phase II study, CTEP #7431
    Meeting Abstract

    Hensley, M. L.; Kravetz, S. J.; Jia, X.; Tew, W. P.; Pereira, L.; Sabbatini, P.; Whalen, C.; Aghajanian, C.; Zarwan, C.; Berlin, S. T.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save